Corcept Therapeutics Insider Sold Shares Worth $2,906,601, According to a Recent SEC Filing
MT newswire2026/10/06 07:2803:28 AM EDT, 10/06/2026 (MT Newswires) -- Sean Maduck, President, Corcept Endocrinology, on October 01, 2026, sold 25,000 shares in Corcept Therapeutics (CORT) for $2,906,601. Following the Form 4 filing with the SEC, Maduck has control over a total of 119,655 common shares of the company, with 9,938 shares held directly and 109,717 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1088856/000119312526414674/xslF345X05/ownership.xml
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
